Skip to main content
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1994 Jul 1;180(1):173–181. doi: 10.1084/jem.180.1.173

Human major histocompatibility complex class II-restricted T cell responses in transgenic mice

PMCID: PMC2191575  PMID: 8006581

Abstract

Transgenic mice expressing human major histocompatibility complex (MHC) class II molecules would provide a valuable model system for studying human immunology. However, attempts to obtain human class II-restricted T cell responses in such transgenic mice have had only limited success, possibly due to an inability of mouse CD4 to interact efficiently with human MHC class II molecules. To circumvent this problem, we constructed recombinant MHC class II genes in which the peptide-binding domain was derived from human DR sequences whereas the CD4-binding domain was derived from mouse I-E sequences. Purified chimeric human/mouse MHC class II molecules were capable of specifically binding DR-restricted peptides. Human B cell transformants that expressed these chimeric MHC class II molecules could present peptide antigens to human T cell clones. Expression of these chimeric class II molecules in transgenic mice led to the intrathymic deletion of T cells expressing superantigen-reactive V beta gene segments, indicating that the chimeric class II molecules could influence the selection of the mouse T cell repertoire. These transgenic mice were fully capable of mounting human DR-restricted immune responses after challenge with peptide or whole protein antigens. Thus, the chimeric class II molecules can serve as functional antigen presentation molecules in vivo. In addition, transgenic mice expressing chimeric class II molecules could be used to generate antigen-specific mouse T cell hybridomas that were capable of interacting with human antigen-presenting cells.

Full Text

The Full Text of this article is available as a PDF (984.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson G., Larhammar D., Widmark E., Servenius B., Peterson P. A., Rask L. Class II genes of the human major histocompatibility complex. Organization and evolutionary relationship of the DR beta genes. J Biol Chem. 1987 Jun 25;262(18):8748–8758. [PubMed] [Google Scholar]
  2. Begovich A. B., Vu T. H., Jones P. P. Characterization of the molecular defects in the mouse E beta f and E beta q genes. Implications for the origin of MHC polymorphism. J Immunol. 1990 Mar 1;144(5):1957–1964. [PubMed] [Google Scholar]
  3. Benoist C., Mathis D. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol. 1990;8:681–715. doi: 10.1146/annurev.iy.08.040190.003341. [DOI] [PubMed] [Google Scholar]
  4. Bill J., Kanagawa O., Woodland D. L., Palmer E. The MHC molecule I-E is necessary but not sufficient for the clonal deletion of V beta 11-bearing T cells. J Exp Med. 1989 Apr 1;169(4):1405–1419. doi: 10.1084/jem.169.4.1405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cammarota G., Scheirle A., Takacs B., Doran D. M., Knorr R., Bannwarth W., Guardiola J., Sinigaglia F. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature. 1992 Apr 30;356(6372):799–801. doi: 10.1038/356799a0. [DOI] [PubMed] [Google Scholar]
  6. Dorn A., Durand B., Marfing C., Le Meur M., Benoist C., Mathis D. Conserved major histocompatibility complex class II boxes--X and Y--are transcriptional control elements and specifically bind nuclear proteins. Proc Natl Acad Sci U S A. 1987 Sep;84(17):6249–6253. doi: 10.1073/pnas.84.17.6249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fujinami R. S., Nelson J. A., Walker L., Oldstone M. B. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression. J Virol. 1988 Jan;62(1):100–105. doi: 10.1128/jvi.62.1.100-105.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gao E. K., Kanagawa O., Sprent J. Capacity of unprimed CD4+ and CD8+ T cells expressing V beta 11 receptors to respond to I-E alloantigens in vivo. J Exp Med. 1989 Dec 1;170(6):1947–1957. doi: 10.1084/jem.170.6.1947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Horn G. T., Bugawan T. L., Long C. M., Erlich H. A. Allelic sequence variation of the HLA-DQ loci: relationship to serology and to insulin-dependent diabetes susceptibility. Proc Natl Acad Sci U S A. 1988 Aug;85(16):6012–6016. doi: 10.1073/pnas.85.16.6012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kim K. J., Kanellopoulos-Langevin C., Merwin R. M., Sachs D. H., Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol. 1979 Feb;122(2):549–554. [PubMed] [Google Scholar]
  11. König R., Huang L. Y., Germain R. N. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature. 1992 Apr 30;356(6372):796–798. doi: 10.1038/356796a0. [DOI] [PubMed] [Google Scholar]
  12. Lamarre D., Ashkenazi A., Fleury S., Smith D. H., Sekaly R. P., Capon D. J. The MHC-binding and gp120-binding functions of CD4 are separable. Science. 1989 Aug 18;245(4919):743–746. doi: 10.1126/science.2549633. [DOI] [PubMed] [Google Scholar]
  13. Lawrance S. K., Karlsson L., Price J., Quaranta V., Ron Y., Sprent J., Peterson P. A. Transgenic HLA-DR alpha faithfully reconstitutes IE-controlled immune functions and induces cross-tolerance to E alpha in E alpha 0 mutant mice. Cell. 1989 Aug 11;58(3):583–594. doi: 10.1016/0092-8674(89)90439-x. [DOI] [PubMed] [Google Scholar]
  14. Lombardi G., Barber L., Aichinger G., Heaton T., Sidhu S., Batchelor J. R., Lechler R. I. Structural analysis of anti-DR1 allorecognition by using DR1/H-2Ek hybrid molecules. Influence of the beta 2-domain correlates with CD4 dependence. J Immunol. 1991 Sep 15;147(6):2034–2040. [PubMed] [Google Scholar]
  15. Nepom B. S., Nepom G. T., Mickelson E., Schaller J. G., Antonelli P., Hansen J. A. Specific HLA-DR4-associated histocompatibility molecules characterize patients with seropositive juvenile rheumatoid arthritis. J Clin Invest. 1984 Jul;74(1):287–291. doi: 10.1172/JCI111413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nepom G. T., Erlich H. MHC class-II molecules and autoimmunity. Annu Rev Immunol. 1991;9:493–525. doi: 10.1146/annurev.iy.09.040191.002425. [DOI] [PubMed] [Google Scholar]
  17. Nepom G. T., Hansen J. A., Nepom B. S. The molecular basis for HLA class II associations with rheumatoid arthritis. J Clin Immunol. 1987 Jan;7(1):1–7. doi: 10.1007/BF00915418. [DOI] [PubMed] [Google Scholar]
  18. Nishimura Y., Iwanaga T., Inamitsu T., Yanagawa Y., Yasunami M., Kimura A., Hirokawa K., Sasazuki T. Expression of the human MHC, HLA-DQW6 genes alters the immune response in C57BL/6 mice. J Immunol. 1990 Jul 1;145(1):353–360. [PubMed] [Google Scholar]
  19. Oldstone M. B. Molecular mimicry and autoimmune disease. Cell. 1987 Sep 11;50(6):819–820. doi: 10.1016/0092-8674(87)90507-1. [DOI] [PubMed] [Google Scholar]
  20. Oldstone M. B. Molecular mimicry as a mechanism for the cause and a probe uncovering etiologic agent(s) of autoimmune disease. Curr Top Microbiol Immunol. 1989;145:127–135. doi: 10.1007/978-3-642-74594-2_11. [DOI] [PubMed] [Google Scholar]
  21. Panina-Bordignon P., Corradin G., Roosnek E., Sette A., Lanzavecchia A. Recognition by class II alloreactive T cells of processed determinants from human serum proteins. Science. 1991 Jun 14;252(5012):1548–1550. doi: 10.1126/science.1710827. [DOI] [PubMed] [Google Scholar]
  22. Roudier J., Rhodes G., Petersen J., Vaughan J. H., Carson D. A. The Epstein-Barr virus glycoprotein gp110, a molecular link between HLA DR4, HLA DR1, and rheumatoid arthritis. Scand J Immunol. 1988 Apr;27(4):367–371. doi: 10.1111/j.1365-3083.1988.tb02359.x. [DOI] [PubMed] [Google Scholar]
  23. Sasazuki T., Iwanaga T., Inamitsu T., Yanagawa Y., Yasunami M., Kimura A., Hirokawa K., Nishimura Y. Expression and function of human major histocompatibility complex HLA-DQw6 genes in the C57BL/6 mouse. Cold Spring Harb Symp Quant Biol. 1989;54(Pt 1):513–520. doi: 10.1101/sqb.1989.054.01.061. [DOI] [PubMed] [Google Scholar]
  24. Sheehy M. J., Scharf S. J., Rowe J. R., Neme de Gimenez M. H., Meske L. M., Erlich H. A., Nepom B. S. A diabetes-susceptible HLA haplotype is best defined by a combination of HLA-DR and -DQ alleles. J Clin Invest. 1989 Mar;83(3):830–835. doi: 10.1172/JCI113965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sleckman B. P., Peterson A., Jones W. K., Foran J. A., Greenstein J. L., Seed B., Burakoff S. J. Expression and function of CD4 in a murine T-cell hybridoma. Nature. 1987 Jul 23;328(6128):351–353. doi: 10.1038/328351a0. [DOI] [PubMed] [Google Scholar]
  26. Tait B. D., Mraz G., Harrison L. C. Association of HLA-DQw3 (TA10-) with type I diabetes occurs with DR3/4 but not DR1/4 patients. Diabetes. 1988 Jul;37(7):926–929. doi: 10.2337/diab.37.7.926. [DOI] [PubMed] [Google Scholar]
  27. Vignali D. A., Moreno J., Schiller D., Hämmerling G. J. Species-specific binding of CD4 to the beta 2 domain of major histocompatibility complex class II molecules. J Exp Med. 1992 Apr 1;175(4):925–932. doi: 10.1084/jem.175.4.925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Vitiello A., Marchesini D., Furze J., Sherman L. A., Chesnut R. W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med. 1991 Apr 1;173(4):1007–1015. doi: 10.1084/jem.173.4.1007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Vu T. H., Begovich A. B., Tacchini-Cottier F. M., Jones P. P. Molecular defects in the non-expressed H-2 E alpha genes of the f and q haplotypes. J Immunol. 1989 Apr 15;142(8):2936–2942. [PubMed] [Google Scholar]
  30. White J., Blackman M., Bill J., Kappler J., Marrack P., Gold D. P., Born W. Two better cell lines for making hybridomas expressing specific T cell receptors. J Immunol. 1989 Sep 15;143(6):1822–1825. [PubMed] [Google Scholar]
  31. Wordsworth B. P., Lanchbury J. S., Sakkas L. I., Welsh K. I., Panayi G. S., Bell J. I. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A. 1989 Dec;86(24):10049–10053. doi: 10.1073/pnas.86.24.10049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Zoschke D., Segall M. Dw subtypes of DR4 in rheumatoid arthritis: evidence for a preferential association with Dw4. Hum Immunol. 1986 Jan;15(1):118–124. doi: 10.1016/0198-8859(86)90322-8. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES